European Coronary Stent Market to Decline to $490 Million by 2016, Despite Growth in Number of Procedures

European Coronary Stent Market to Decline to $490 Million by 2016, Despite Growth in Number of Procedures

Drug-Eluting Stents and Innovations in Bioabsorbable Stents Will Maintain Premium Prices and Help Support the Market, According to Millennium Research Group

TORONTO--(BUSINESS WIRE)--According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, while the number of coronary stenting procedures performed will show steady growth, stent selling prices will decline significantly, resulting in a decline in overall market value that will average 3.5 percent per year through 2016. One exception to the overall market decline will be drug-eluting bioresorbable scaffolds and biodegradable polymer drug eluting stents (DES), which are expected to be adopted over this period and limit the slide in market value.


Recent innovations in DES stents show promise. Biodegradable polymer drug-eluting stents, for example, offer a better safety profile than durable-polymer drug-eluting stents, as late-stent thrombosis is largely attributed to the polymer that binds the drug to the stent. In biodegradable polymer stents, a polymer controls drug release but then disappears, leaving a bare metal stent. Examples of stents with biodegradable polymers are Biosensors International's BioMatrix, Terumo Medical's Nobori, Sahajanand Medical Technologies' Supralimus and Boston Scientific's fourth generation Synergy stent, which is still in development.

In contrast to bioabsorbable polymer stents, which still leave behind a bare metal stent, bioresorbable vascular scaffolds disappear completely, with the promise of vessel wall regrowth. A number of companies are working on scaffold products, including Abbott Vascular with ABSORB, REVA Medical with ReZolve, OrbusNeich and BIOTRONIK. Bioresorbable scaffolds were soft launched in 2011, and a full launch is expected across Europe by the end of 2012.

"These bioresorbable devices have the potential to revolutionize the market," said MRG Principal Analyst Karene Dumoulin. "They do need to demonstrate that they yield a decrease in the occurrence of late stent thrombosis or provide other advantages not available with current DES on the market, such as complete vascular restoration and motion, which is promised by Abbott Vascular's ABSORB device."

Millennium Research Group's European Markets for Interventional Cardiology Devices 2012 report includes procedure, unit, average selling price and revenue information, along with market drivers and limiters and competitive landscape for coronary stents, percutaneous transluminal coronary angioplasty (PTCA) balloon catheters, accessory devices, and intravascular imaging catheters and pressure guidewires sold in France, Germany, Italy and the United Kingdom.

About Millennium Research Group

Millennium Research Group (, a Decision Resources Group company (, is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing MarketrackTM projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

Decision Resources Group
Christopher Comfort, 781-993-2597
[email protected]
Millennium Research Group
Alex Jablokow, 617-599-8613
[email protected]